When building your watch list, look for stocks with an 80 or higher RS Rating. Stryker just cleared that benchmark with an upgrade from 78 to 81.
Hone Your Stock-Picking Skills By Focusing On These Factors
IBD's unique RS Rating identifies market leadership by showing how a stock's price movement over the last 52 weeks compares to that of other stocks on the major indexes.
Decades of market research shows that the best-performing stocks tend to have an RS Rating of over 80 in the early stages of their moves.
Stryker is building a consolidation with a 406.19 buy point. See if it can break out in volume at least 40% higher than normal.
While earnings growth declined in the company's most recent quarterly report from 16% to 14%, sales grew 12%, up from 11% in the prior report.
Stryker holds the No. 10 rank among its peers in the Medical-Products industry group. Penumbra, Boston Scientific and Insulet are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
